These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 30626831)

  • 1. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Int J Rheum Dis; 2019 Mar; 22(3):468-472. PubMed ID: 30406967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
    Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
    Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
    Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.
    Chen YM; Lin CH; Lan TH; Chen HH; Chang SN; Chen YH; Wang JS; Hung WT; Lan JL; Chen DY
    Rheumatology (Oxford); 2015 Jul; 54(7):1244-9. PubMed ID: 25587177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.
    Mok CC; Penn HJ; Chan KL; Tse SM; Langman LJ; Jannetto PJ
    Arthritis Care Res (Hoboken); 2016 Sep; 68(9):1295-302. PubMed ID: 26749299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine in lupus pregnancy.
    Clowse ME; Magder L; Witter F; Petri M
    Arthritis Rheum; 2006 Nov; 54(11):3640-7. PubMed ID: 17075810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
    Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
    J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
    Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
    Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial hydroxychloroquine monotherapy in systemic lupus erythematosus: report of three cases.
    Ichikawa K; Kirino Y; Kunishita Y; Kishimoto D; Takase-Minegishi K; Yoshimi R; Nakajima H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):259-264. PubMed ID: 33533686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study.
    Leroux M; Desveaux C; Parcevaux M; Julliac B; Gouyon JB; Dallay D; Pellegrin JL; Boukerrou M; Blanco P; Lazaro E
    Lupus; 2015 Nov; 24(13):1384-91. PubMed ID: 26082465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.